Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
On April 28, 2022, Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for May 5, 2022, at 8:30 a.m. ET to discuss its financial results for Q1 2022, which ended on March 31, 2022. The company focuses on developing tolerogenic therapies using its ImmTOR® platform, aimed at mitigating unwanted immune responses. Stakeholders can participate via telephone or access the live and archived webcast on the company’s website.
- Selecta is leveraging its ImmTOR® platform to develop innovative therapies.
- The company has multiple proprietary and partnered programs targeting enzyme therapies and autoimmune diseases.
- None.
WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, May 5, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.
Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10157872. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
When will Selecta Biosciences announce its Q1 2022 financial results?
What is the ImmTOR® platform by Selecta Biosciences?
How can I participate in the Selecta Biosciences conference call?
Where can I find the webcast of the Selecta Biosciences conference call?
